We can't find the internet
Attempting to reconnect
13265.1 PFLS-LS
Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects
Résumé
Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects
Textes supplémentaires
Abstract
Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.
Participants
Liane Höfferer
Wirtschaftspartner
CSL Behring AG CHE-105.544.325 Liane Höfferer Wankdorfstrasse 10 3014 Bern BE CH
Dominik Schaer
Kontaktperson
dominik.schaer@usz.ch
USZ Universitätsspital Zürich Dominik Schaer Rämistrasse 100 8091 Zürich ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2012-02-29
- Date de fin
- 2015-12-31
- Coûts totaux approuvés
- CHF 1101000.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T115 Medical technology 100.0%